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Abstract
Angioedema in the mouth or upper airways is a feared adverse reaction to angiotensin-converting enzyme inhibitor
(ACEi) and angiotensin receptor blocker (ARB) treatment, which is used for hypertension, heart failure and diabetes
complications. This candidate gene and genome-wide association study aimed to identify genetic variants predisposing
to angioedema induced by these drugs. The discovery cohort consisted of 173 cases and 4890 controls recruited in
Sweden. In the candidate gene analysis, ETV6, BDKRB2, MME, and PRKCQ were nominally associated with
angioedema (p < 0.05), but did not pass Bonferroni correction for multiple testing (p < 2.89 × 10−5). In the genome-wide
analysis, intronic variants in the calcium-activated potassium channel subunit alpha-1 (KCNMA1) gene on chromosome
10 were significantly associated with angioedema (p < 5 × 10−8). Whilst the top KCNMA1 hit was not significant in
the replication cohort (413 cases and 599 ACEi-exposed controls from the US and Northern Europe), a meta-analysis of
the replication and discovery cohorts (in total 586 cases and 1944 ACEi-exposed controls) revealed that each variant
allele increased the odds of experiencing angioedema 1.62 times (95% confidence interval 1.05–2.50, p= 0.030).
Associated KCNMA1 variants are not known to be functional, but are in linkage disequilibrium with variants
in transcription factor binding sites active in relevant tissues. In summary, our data suggest that common variation
in KCNMA1 is associated with risk of angioedema induced by ACEi or ARB treatment. Future whole exome or genome
sequencing studies will show whether rare variants in KCNMA1 or other genes contribute to the risk of ACEi- and ARB-
induced angioedema.
Introduction
Angiotensin-converting enzyme inhibitor (ACEi) and
angiotensin receptor blocker (ARB) containing medications
are often used for hypertension, heart failure and diabetes
complications, and currently 14% of the population in
Sweden is treated with these drugs [1]. Although being
mostly effective and safe, around 0.2–0.7% of patients
starting an ACEi, and 0.1–0.2% starting an ARB experience
the adverse drug reaction (ADR) angioedema [2–6]. Com-
pared with other populations, the risk is higher in African
Americans, suggesting a genetic effect modification [6–8].
The reaction is not dose-related and displays large dis-
crepancies in time to onset, ranging from hours to years
[9, 10].
ACEi- and ARB-induced angioedema is characterised by
swelling of the reticular dermis and subcutaneous skin
layers or mucosa [9, 11, 12]. It is usually localised to the
head and neck region, and may become life threatening
when breathing is impaired due to swelling in the oral
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cavity, tongue, pharynx or larynx [12]. In rare instances the
intestines or genitals may be involved [13]. The patho-
physiological mechanism is believed to involve the accu-
mulation of the vasoactive peptide bradykinin [11, 12].
ACEis directly inhibit the inactivation of bradykinin while
blocking the conversion of angiotensin I to angiotensin II
[14]. ARBs have no direct effect on bradykinin [15],
but may increase bradykinin levels through indirect inhi-
bition of ACE and metallo-endopeptidase [16]. Drugs
conventionally used in immune-mediated angioedema such
as antihistamines, glucocorticoids and adrenaline have
limited effects on ACEi- and ARB-induced angioedema
[12, 17]. Alternative treatments are the bradykinin receptor
antagonist icatibant, complement C1-esterase inhibitors,
ecallantide, and fresh frozen plasma, but definite proof of
their benefit is still lacking [12, 18, 19].
Two recent reviews describe nine studies with possible
genetic associations to ACEi-induced angioedema
[20, 21]. The majority are case–control studies that focus
on candidate genes in bradykinin pathways. Three studies
found significant associations with variation in the
bradykinin-degrading enzyme aminopeptidase P gene
XPNPEP2 [22–24], and one found an association with a
variant of the type 2 bradykinin receptor gene (BDKRB2)
[25]. Mutations in serpin super family and clotting factor
genes causing the rare condition hereditary angioedema
are also of interest [26]. It is recommended that these
patients avoid ACEis [27], but a mutation in the Serpin
Family E Member 1 gene (SERPINE1) has been described
in at least one patient with apparent ACEi-induced
angioedema [28], and a mutation in the Coagulation Fac-
tor XII gene (F12) in another [29]. None of the mentioned
candidate genes was significantly associated in the only
published genome-wide association study (GWAS) on
ACEi-induced angioedema [30]. The main findings were a
non-significant association between risk of angioedema
and the ETS Variant Transcription Factor 6 gene (ETV6)
in African Americans, while a variant of the Protein
Kinase C Theta gene (PRKCQ) tended to be protective in
European Americans [30]. Furthermore, in a candidate
gene analysis of the same study, a nominal association
with the bradykinin degrading enzyme Neprilysin gene
(Membrane Metalloendopeptidase, MME) was detected in
African Americans [30]. Neprilysin-inhibitors are a recent
addition to the arsenal of agents used in cardiovascular
disease, and are known to augment the risk of angioedema
in ACEi-treated patients [31, 32].
The objective of this genome-wide association and
candidate gene study was to investigate whether any
genetic variants predispose to angioedema associated
with ACEi or ARB treatment in a Northern European
population, and if so to assess the functionality of detected
associations.
Subjects and methods
Ethics statement
Research was carried out in accordance with the latest
update of the Declaration of Helsinki. Written informed
consent was obtained from all participants in the dis-
covery and replication cohorts. The study protocols were
approved by Ethics Committees or Institutional Review
Boards in each country. Please see the Supplementary
Methods for details.
Discovery cohort description
Angioedema cases associated with ACEi or ARB treatment
reported to the Swedish national ADR registry at the
Medical Products Agency or referred from collaborating
clinicians were recruited according to SWEDEGENE’s
standardised procedure (www.swedegene.se). Please see
the Supplementary Methods for details. Inclusion and
exclusion was according to published phenotype criteria
[11]. All cases were reviewed and adjudicated by a clinical
expert in allergology. Patients provided an EDTA blood
sample that was stored at −70 °C until DNA extraction.
Unrelated population controls were obtained from the
Swedish Twin registry. The subgroup treated controls had
collected at least two prescriptions of an ACEi at a Swedish
pharmacy according to the Swedish Prescribed Drug Reg-
ister [1, 33]. Indications for treatment were searched for in
the Swedish National Patient Register, but were only
available for 71% of the controls since the register has a low
sensitivity for primary care diagnosis [34]. Controls who
had been given the diagnoses angioedema or larynx-oedema
were excluded [35].
Discovery genotyping, imputation and data analysis
Cases were genotyped on the Illumina HumanOmni2.5
BeadChip array and controls had previously been geno-
typed on the Illumina HumanOmniExpress 700 K Bead-
Chip (Illumina, CA, USA). Quality control and data
management was done with PLINK v1.9 [36]. Sex chro-
mosomes were filtered out at an early stage. The resulting
merged data set included 622992 single nucleotide poly-
morphisms (SNPs). Imputation of genotypes was performed
with PhaseIT [37] and Impute v2 using 1000 genomes as
reference [38]. Post-imputation, variants with MAF below
1% or a missing rate above 2%, and individuals with more
than 2% missing markers were filtered out. SNPs deviating
from the Hardy-Weinberg equilibrium (p < 10−6) among
controls were removed. The final dataset contained 7585599
SNPs. The quantile–quantile (Q-Q) plot for analysis
of cases vs all controls after imputation is shown in
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Supplementary Fig. S1. Principal component analysis was
performed on non-imputed data in order to account for
possible population stratification. Logistic regression was
used to estimate univariate and multiple models. SNP
effects were modelled as additive. The conventional
genome-wide significance threshold p < 5 × 10−8 was used
to correct for multiple testing [39]. PLINK v1.9 was used
for genome-wide analyses, and R 3.2.2 (R Foundation for
Statistical Computing, Vienna, Austria) for individual SNP
analyses.
In addition, we performed candidate gene analyses for
BDKRB2, ETV6, F12, MME, PRKCQ, and SERPINE1 in the
imputed data set [20, 21]. All variants within the chromo-
somal positions (Table 1) ±10,000 bases upstream and
downstream were extracted. XPNPEP2, which is located on
the X chromosome, could not be evaluated since sex chro-
mosomes were filtered out pre-imputation. SNP effects were
modelled as additive. The number of tested genetic variants
was 1730, and the Bonferroni cut-off for correction for
multiple testing was p < 2.89 × 10−5 (= 0.05/1730 SNPs).
All 173 cases were tested vs 4890 unmatched controls, and
vs the 1345 matched controls.
Power calculation
Our sample size was powered to detect common genetic
variants with effect sizes of clinical utility [40]. Power
calculations were based on an ADR prevalence of 1%, and a
minor allele frequency (MAF) of 10%, 173 cases, 4890
unmatched and 1345 matched controls, and an additive
genetic model. Given a genome-wide significance level of
5 × 10−8, we had 80% power to detect an odds ratio (OR) of
3.0 when using unmatched controls, and 80% power
to detect an OR of 3.1 when using matched controls
(Supplementary Fig. S2a, b). Given a candidate gene
significance level of 2.89 × 10−5, we had 80% power to
detect an OR of 2.4 when using unmatched controls, and
80% power to detect an OR of 2.5 when using matched
controls (Supplementary Fig. S3a, b).
Replication cohort description
Data from the published ACEi-angiodema GWAS cohort
from Vanderbilt and Marshfield, USA, was obtained
through collaboration [30]. Cases were defined as patients
who developed swelling of the lips, pharynx or face for the
first time while taking an ACE inhibitor. Controls had been
treated with an ACEi for at least 6 months without devel-
oping angioedema.
The Northern European cohort was recruited in four
countries, and was part of the PREDICTION-ADR study.
Please see the Supplementary Methods for details. In
Sweden, cases were recruited according to SWEDEGENE’s
standardised procedure. In Denmark, cases were referred by
physicians at participating hospitals and a general practi-
tioner. In the Netherlands, cases were referred by physicians
at participating hospitals or identified by screening elec-
tronic medical records from all hospital admissions for
angioedema. In the UK, cases were identified by referral
from consultant immunologists, and by review of archived
clinical letters. The expert who assessed the discovery cases
also assessed all replication cases and used identical criteria
[11]. Treated controls from Sweden were recruited by col-
laborating clinicians. Danish treated controls were selected
from existing databases [41]. Dutch treated controls were
participants of Utrecht Cardiovascular Pharmacogenomics
(UCP) studies [42]. British treated controls were patients in
the Genetics of Diabetes Audit and Research Tayside Study
(GoDARTS) [43]. Cases and controls provided a blood or
saliva sample (2 ml Oragene® OG-500 collection kit, DNA
Genotek, Canada). Blood samples were kept at −70 °C and
saliva samples at room temperature until DNA extraction
according to standard procedures.
Replication genotyping and meta-analysis
The American cohort was genotyped using a 610Quadv1.B
Illumina Bead Chip. Genotyping of the Northern European
replication cohort was performed on the Applied Biosys-
tems 7500 Fast Real-Time PCR System (Thermo Fisher
Scientific, Waltham, Massachusetts, USA) according to
standard procedures. The TaqMan SNP Genotyping Assay
kit for rs2253202 (C__15924034_20) was used.
Meta-analysis was performed using one genotyped SNP
in the Northern European replication cohort, and summary
data for this SNP in the published American GWAS [30]
and the discovery GWAS. Logistic regression was used to
evaluate the association between the SNP and angioedema.
Table 1 Candidate genes for angiotensin-converting enzyme inhibitor-
induced angioedema tested in the study. Chromosomal position is
according to the Genome Reference Consortium Human genome
build 37.
Genes Chromosome Start position End position
BDKRB2 14 96671016 96710666
ETV6 12 11802788 12048336
F12 5 176829141 176836577
MME 3 154741913 154901497
PRKCQ 10 6469105 6622263
SERPINE1 7 100770370 100782547
The genes encode Bradykinin Receptor B2 (BDKRB2), ETS Variant
Transcription Factor 6 (ETV6), Coagulation Factor XII (F12), Neprilysin
or Membrane Metalloendopeptidase (MME), Protein Kinase C Theta
(PRKCQ), and Serpin Family E Member 1 (SERPINE1). All variants
within the chromosomal positions plus 1000 bases upstream and 1000
bases downstream were extracted.
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The SNP effect was modelled as additive. Meta-analysis
was performed using a fixed-effect model in the metafor
R-package [44]. The cut-off for a statistically significant
association was set to p < 0.05.
Functional analysis
Functional annotations were obtained by intersecting top
GWAS SNPs and SNPs in high linkage disequilibrium (LD)
with transcription factor binding sites reported by the
ENCODE project, and with chromatin state models from
the Roadmap Epigenomics project [45–47]. Chromatin state
was based on deoxyribonuclease (DNAse) I hypersensitive
clusters and histone modifications that indicate active
regulatory regions (H3K4me3 and H3K27ac). We used
annotations in skin, mucosa-derived tissues, oesophagus,
aorta, smooth muscle and the umbilical vein endothelial cell
line HUVEC. Motif analysis was based on a position
weight matrix library and enhancer tissue-specific motif
clustering [47–49].
Results
Discovery cohort characteristics
One hundred and seventy-three cases of angioedema asso-
ciated with ACEi and/or ARB treatment passed adjudica-
tion. Almost all were of Swedish origin (93.1%), and there
were more males than females (Table 2). One outlier among
the cases was detected with principal component analysis,
but not removed (Supplementary Fig. S4a, b). Most patients
had a history of cardiovascular disease, including hyper-
tension, angina pectoris, myocardial infarction or stroke,
and approximately one in four suffered from diabetes.
The angioedema event was in 144 patients associated with
ACEi treatment, most frequently enalapril and ramipril. In
31 patients, the event was associated with an ARB, most
frequently candesartan and losartan. Two patients devel-
oped angioedema during treatment with both an ACEi
and an ARB (enalapril/candesartan and ramipril/losartan
respectively). Frequent co-medications during the three
months preceding the onset of angioedema were diuretics
(47.4%), lipid-modifying agents (44.5%), beta-blockers
(42.8%), antiplatelet drugs (42.2%), and selective calcium
channel blockers (31.8%).
Data from 4890 unrelated population controls were
obtained from the Swedish Twin Registry [33]. The sub-
group of treated controls (n= 1345) had collected at least
two prescriptions of an ACEi at a Swedish Pharmacy
without being diagnosed with angioedema or larynx-
oedema (Table 2). Sex distribution among treated controls
was similar to that of the cases with more males than
females. Hypertension, diabetes and heart failure were
common among the treated controls that had data on diag-
noses (n= 956). The most frequently prescribed ACEis
were enalapril and ramipril.
Discovery cohort genome-wide analysis data
analysis
The calcium-activated potassium channel subunit alpha-1
(KCNMA1) gene on chromosome 10 was significantly
associated with angioedema on a genome-wide level. The
top hit in intron 1 of KCNMA1 was rs2253201 (OR= 2.47,
95% CI= 1.79–3.42, p= 4.17 × 10−8), and several nearby
Table 2 Baseline characteristics of cases and treated controls in the
discovery cohort.
Cases (N= 173) Controls (N= 1345)
Age at onset, mean (range) 65.6 [31–91] 68.9 [49–96]
Sex, N (%)
Female 72 (41.6) 481 (36.0)
Male 101 (58.4) 864 (64.0)
Indications for treatmenta, N (%)
Hypertension 165 (95.4) 668 (69.9)
Diabetes 40 (23.1) 230 (24.1)
Heart failure 6 (3.4) 162 (16.9)
Type of ACEib, N (%)
C09AA02 Enalapril 116 (80.6) 1055 (78.4)
C09AA05 Ramipril 24 (16.7) 239 (17.8)
C09AA03 Lisinopril 3 (2.1) 27 (2.0)
C09AA01 Captopril 0 (0) 13 (1.0)
C09AA08 Cilazapril 0 (0) 8 (0.6)
C09AA06 Quinapril 1 (0.7) 1 (0.1)
C09AA09 Fosinopril 0 (0) 1 (0.1)
C09AA10 Trandolapril 0 (0) 1 (0.1)
Type of ARBc, N (%)
C09CA06 Candesartan 12 (41.4) N/A
C09CA01 Losartan 11 (37.9) N/A
C09CA04 Irbesartan 4 (13.8) N/A
C09CA07 Telmisartan 1 (3.4) N/A
C09CA03 Valsartan 1 (3.4) N/A
Drugs were categorised using the World Health Organization (WHO)
Collaborating Centre for Drug Statistics Methodology International
Anatomical Therapeutic Chemical (ATC) classification.
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin
receptor blocker, N number of subjects, N/A not available.
aData available for all 173 cases and for 956 of 1345 treated controls.
Percentages are calculated using only individuals with data.
bData available for all 144 ACEi-treated cases and for all 1345 of
ACEi-treated controls. Two cases were treated with both an ACEi and
an ARB.
cData available for none of the controls and for all 29 ARB-
treated cases.
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SNPs had p values around 10−7 (Table 3a, Supplementary
Table S1). After imputation, five additional SNPs in intron
1 of KCNMA1 were associated on a genome-wide level:
rs2253202 (OR= 2.47, 95% CI= 1.79–3.42, p= 4.31 ×
10−8), rs2673471 (OR= 2.47, 95% CI= 1.79–3.41, p=
4.35 × 10−8) and rs2619635, rs2670121 and rs2673455
(all OR= 2.47, 95% CI= 1.79–3.41, p= 4.59 × 10−8)
(Fig. 1a, Table 3b, Supplementary Table S2). Comparisons
with the 1345 treated controls supported that the associa-
tion with KCNMA1 was not due to confounding by indi-
cation (OR= 2.34, 95% CI= 1.67–3.29, p= 8.91 × 10−7)
(Figs. 1b and 2, Table 3c).
Fig. 1 Manhattan plot of genome-wide association analysis. Ana-
lysis of 7585599 genome-wide single nucleotide polymorphisms in
173 cases of angioedema associated with angiotensin-converting
enzyme inhibitors and/or angiotensin receptor blockers adjusted by sex
and genetic principal components 1–4. The threshold for genome-wide
significance (p < 5 × 10−8) is indicated by the red line on the x-axis
where the scale is –log10(p). a Intronic SNPs in the Calcium-activated
potassium channel subunit alpha-1 (KCNMA1) gene on chromosome
10 were significantly associated on a genome-wide level when cases
were compared with all 4890 controls. b Associations were similar,
but did not reach genome-wide significance, when cases were com-
pared with 1345 controls matched for treatment.
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Discovery cohort candidate gene analysis
ETV6, BDKRB2, MME, and PRKCQ were nominally
associated with angioedema (p < 0.05), but none of
the candidate genes was significantly associated after
correction with multiple testing (p < 2.89 × 10−5) (Fig. 3a,
Table 4a, Supplementary Table S3). Results were con-
sistent when cases were compared with matched controls
(Fig. 3b, Table 4b). The only published candidate SNPs
present in our data were the presumed protective PRKCQ
rs500766 and deleterious MME rs989692 [30]. Odds
ratios for these SNPs were close to 1 in our study
(Table 5).
Replication cohort characteristics
The American cohort included 175 angioedema cases and
489 ACEi-exposed controls [30]. Sixty-six of the cases
were of African, and 109 of European descent. Ethnic origin
of the controls was 157 African, 330 European, and two
unknown. The Northern European cohort included 238
angioedema cases and 110 treated controls. Specifically,
there were 96 cases and 38 controls from Sweden, 60 cases
and 20 controls from Denmark, 64 cases and 52 controls
from the Netherlands, and 18 cases from the UK. All cases
had been treated with an ACEi, and one also with an ARB.
All controls were treated with an ACEi, and eight also with
an ARB.
Replication and meta-analysis
We sought replication for the top hit rs2253202 in the
American cohort [30] and the Northern European cohort
divided into Swedish-Danish and Dutch-British (Fig. 3).
All individual cohorts had odds ratios above 1, but the
results did not reach significance. Meta-analysis of the
413 cases and 599 ACEi-exposed controls included in
the replication likewise gave non-significant results
(OR= 1.25, 95% CI= 0.85−1.83, p= 0.255) (Fig. 3).
The discovery cohort was then added to the meta-analysis,
making a grand total of 586 cases and 1944 ACEi-
exposed controls, which rendered a statistically significant
association between rs2253202 and angioedema (OR=
1.62, 95% CI= 1.05–2.50, p= 0.030) (Fig. 4). This
means that the odds of experiencing angioedema
increased 1.62 times per minor allele, i.e. that the risk
would be (1.62)2= 2.62 times increased in homozygous
carriers of rs2253202.
Fig. 2 Estimated odds ratios for associations with rs2253202 in
KCNMA1. A forest plot of the association with rs2253202 in the 173
discovery cases compared with all 4890 controls and with 1345 treated
controls. Estimated odds ratios (OR) with 95% confidence intervals
(CI), p value and numbers (N) included are shown. The effect is
adjusted for sex and genetic principal components 1–4.
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Fig. 3 Manhattan plot of candidate gene association analysis.
Analysis of 1730 candidate gene single nucleotide polymorphisms in
173 cases of angioedema associated with angiotensin-converting
enzyme inhibitors and/or angiotensin receptor blockers adjusted by sex
and genetic principal components 1–4. The threshold for candidate
gene-wide significance (p < 2.89 × 10−5) is indicated by the red line on
the x-axis where the scale is –log10(p). a None of the candidate genes
BDKRB2, ETV6, F12, MME, PRKCQ or SERPINE1 was significantly
associated when cases were compared with all 4890 controls. b Results
were consistent when cases were compared with 1345 controls mat-
ched for treatment.
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Table 4 Top hits in imputed results for each of the candidate genes ETV6, BDKRB2, MME, PRKCQ, SERPINE1, and F12 including 1000 bases
upstream and downstream (a) when compared with unmatched controls, and (b) when compared with matched controls.
CHR SNP BP N OR L95 U95 P GTPS MAF case MAF control Location Gene
(a)
12 rs113768037 12006062 5055 1.793 1.25 2.572 0.001525 C/A 0.108 0.065 Intron ETV6
14 rs4905462 96680574 5046 1.455 1.123 1.885 0.00452 A/G 0.222 0.165 Intron BDKRB2
3 rs3773896 154824685 5047 1.432 1.102 1.859 0.007161 C/A 0.222 0.168 Intron MME
10 rs12784332 6471961 5063 0.7548 0.6046 0.9425 0.01302 T/C 0.387 0.452 Intron PRKCQ
7 rs2227668 100774855 4991 0.7516 0.5446 1.037 0.0824 A/G 0.131 0.166 Intron SERPINE1
5 rs4314418 176836426 4997 0.4384 0.1073 1.79 0.2506 A/C 0.006 0.013 Intron F12
(b)
14 rs4900315 96680903 1513 1.444 1.131 1.843 0.003166 C/T 0.341 0.268 Intron BDKRB2
12 rs113768037 12006062 1514 1.747 1.186 2.573 0.004774 C/A 0.108 0.065 Intron ETV6
3 rs3773896 154824685 1513 1.462 1.104 1.937 0.008019 C/A 0.222 0.165 Intron MME
10 rs10906559 6475947 1507 0.764 0.6073 0.9612 0.02157 T/C 0.367 0.426 Intron PRKCQ
7 rs7459187 100785438 1497 0.7151 0.4979 1.027 0.06941 T/C 0.109 0.145 Downstream SERPINE1
5 rs4314418 176836426 1501 0.3722 0.08915 1.554 0.1754 A/C 0.006 0.016 Intron F12
CHR chromosome, BP base pair (chromosome position), N number of study participants, OR odds ratio, L95 and U95 lower and upper confidence
interval, P p value, MAF minor allele frequency, GTPS genotypes minor/major allele, E exponent of 10.
Table 5 Results for candidate SNPs that previously have been associated with angiotensin-converting enzyme inhibitor-induced angioedema [30].
All cases are compared with unmatched controls.
CHR SNP BP N OR L95 U95 P GTPS MAF case MAF control Gene
10 rs500766 6550590 5063 1.146 0.9074 1.446 0.2531 T/C 0.315 0.280 PRKCQ
3 rs989692 154801365 5063 0.975 0.7836 1.213 0.8199 T/C 0.468 0.484 MME
CHR chromosome, BP base pair (chromosome position), N number of study participants, OR odds ratio, L95 and U95 lower and upper confidence
interval, P p value, MAF minor allele frequency, GTPS genotypes minor/major allele, E exponent of 10.
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Odds Ratio
Swedish discovery cohort
Dutch - British replication cohort
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82/52
156/58
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1.25 [0.85, 1.83]Odds ratio (excluding Swedish discovery cohort, p = 0.255) 
Odds ratio (overall, p = 0.030)
Fig. 4 Meta-analysis. Meta-analysis of the top single nucleotide
polymorphism rs2253202 in the replication cohorts from the US [30]
and Northern Europe. Meta-analysis was performed with and without
the Swedish discovery cohort using a fixed-effect model in the metafor
R-package. Logistic regression was used to evaluate the association
between the SNP and angioedema. SNP effects were modelled as
additive. Estimated odds ratios with 95% confidence intervals (CI),
p value and numbers (N) included are shown. The cut-off for a sta-
tistically significant association was set to p < 0.05.
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Functional analysis
The six significantly associated SNPs in the first intron
of the KCNMA1 gene are in a haplotype block spanning
∼0.1 Mb, and lack evidence of functional activity. They are
in high LD (r2 > 0.8) with 15 non-coding SNPs located in
enhancer elements defined in several angioedema relevant
tissues such as skin, mucosa, oesophagus, aorta, visceral
smooth muscle and endothelial cells (Supplementary
Tables S4a, b, and Supplementary Fig. S5). According to
motif analyses, eight of the SNPs alter binding sites for
transcription factors enriched in skin, mucosa or smooth
muscle (Supplementary Table S3b) [47]. Previous results
from chromatin immunoprecipitation with massively par-
allel DNA sequencing (ChIP-seq) point to the SNP
rs816827 G > A that overlaps binding sites of 22 tran-
scription factors in different cell lines (Supplementary
Fig. S6) [46, 47, 49]. Tissue-specific analyses show that
rs816827 alters binding motifs for transcription factors
enriched in enhancer elements in skin (orange), mucosa
(pink) and smooth muscle (brown) (Supplementary
Table S4b). The TRAP tool [49] indicates that the tran-
scription factor MAF, which is expressed in for example
skin, oral mucosa, oesophagus, aorta and smooth muscle,
would bind significantly stronger to the minor than the
major allele (difference log(p) for two alleles=−0.812 or
A/p value= 0.0253 vs G/p value= 0.164).
Discussion
This study aimed to identify common genetic risk factors for
angioedema induced by ACEi or ARB treatment. Genetic
variants in the calcium-activated potassium channel subunit
alpha-1 (KCNMA1) gene were significantly associated
with angioedema on a genome-wide level (p < 5 × 10−8).
Calcium-activated potassium channel genes are expressed
in vascular smooth muscle and endothelium, and encode
effector proteins crucial for control of vascular tone and
blood pressure [50]. We ascertained that our finding was not
due to confounding by indication for treatment by redoing
the analysis using only ACEi-treated controls. Furthermore,
meta-analysis of four cohorts of cases and treated controls
supported the association between KCNMA1 and ACEi- or
ARB-induced angioedema (Fig. 3).
The KCNMA1 intron 1 variants significantly associated
with angioedema in our study lack evidence of functional
activity, but are in linkage disequilibrium with several
genetic variants located in regulatory elements. Motif
analyses indicate that one variant in particular alters
binding sites for tissue-specific transcription factors, which
could lead to deregulation of a target gene. The target gene
could be distant, but it is more plausible that it is KCNMA1
itself. KCNMA1 encodes the pore-forming alpha subunit of
the large-conductance calcium-dependent potassium big K
(BK) channel, which is important for the repolarization of
the cell membrane [50]. A study using an alpha subunit
BK channel knockout mouse model suggested that this
gene modulates the renin-angiotensin-aldosterone system
[51]. KCNMA1 is one among several genes considered to
be involved in control of vascular tone and hypertension
[50, 52]. A previous GWAS detected an association
between a KCNMA1 intron 1 SNP (rs603788, GRCh37
chr10: 79211262) and diastolic blood pressure in a sub-
group of 3014 elderly patients (p= 9.37 × 10−7) [53].
In a candidate gene study, a KCNMA1 intron 17 SNP
(rs16934182, GRCh37 chr10: 78778734) was nominally
associated with severe systolic hypertension (p= 0.03),
and severe general hypertension (p= 0.04) [54]. These
two intronic SNPs are not in LD with the six intron 1
variants significantly associated in our study (GRCh37
chr10:79356393-79359111) [55].
Genetic variants of calcium/potassium channel genes
have previously been implicated in studies on ACEi-
induced ADRs. A GWAS on ACEi-induced cough detected
an association with the calcium-activated potassium channel
gene KCNMB2 [56], while another GWAS found an asso-
ciation with the calcium-binding potassium channel-
interacting protein gene KCNIP4 [57]. A clinical study
showed that patients who reacted with angioedema to an
ACEi were more often treated with a calcium channel
blocker than those who reacted with cough [58]. Further-
more, angioedema is in rare cases triggered by a calcium
channel blocker (e.g. amlodipine) or potassium channel
blocker (e.g. amiodarone) alone [59, 60]. It is thus reason-
able to believe that deficient transport of calcium and/or
potassium across the cell membrane plays a role in the
development of angioedema.
In addition, we analysed data for the candidate genes
BDKRB2, ETV6, F12, MME, PRKCQ, and SERPINE1.
There was no significant association with single nucleotide
polymorphisms in the candidate genes after correcting for
multiple testing. ETV6 showed promising results with
relatively high odds ratios and p values around 0.001.
A larger sample size would be needed to determine whether
any candidate gene is truly associated with angioedema
induced by ACEi or ARB treatment.
A strength of this study is that the cases were well-
characterised and the diagnostic accuracy was high. There
are also limitations. First, matching of controls was done
using ACEi exposure as a proxy for the indication for
treatment. We were thus unable to identify whether treated
controls were prescribed ACEis for hypertension, which
was the most common diagnosis among cases. Secondly,
although this is the largest GWAS on ACEi- or ARB-
induced angioedema in people of European ancestry to date,
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the low number of cases does not provide enough power to
detect association with rare variants. Nor could we show
whether the trait in question is affected by multiple weakly
associated variants that interact to increase the risk.
Our GWAS suggests that common genetic variants
of KCNMA1 are associated with risk of ACEi- or ARB-
induced angioedema. Comparisons between cases and
treated controls confirm that the finding is not due to con-
founding by indication. Meta-analysis of replication cohorts
from the US [30] and Northern Europe together with the
discovery cohort further supports the association. This is a
step forward in the understanding of mechanisms behind
ACEi- or ABR-induced angioedema. It is, however, rea-
sonable to believe that intron 1 of KCNMA1 is only one of
several susceptibility loci. Future studies based on whole
exome or genome sequencing will show whether rare cod-
ing variants contribute to the risk of ACEi- or ABR-induced
angioedema to a clinically important degree. When the
complete picture is known, and patients have DNA
sequence data available in the medical record before treat-
ment, personalised medical decisions can be used to prevent
this potentially fatal ADR.
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